Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Precision BioSciences. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Precision BioSciences's earnings available for a low price, and how does
this compare to other companies in the same industry?
Precision BioSciences's earnings are expected to grow by 19.3% yearly, however this is not considered high growth (20% yearly).
Precision BioSciences's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Precision BioSciences's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
A company's financial position is much like your own financial position,
it includes everything you own
The boxes below represent the relative size of what makes up
Precision BioSciences's finances.
The net worth of a company is the difference between its assets and liabilities.
Precision BioSciences is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Precision BioSciences's cash and other short term assets cover its long term commitments.
This treemap shows a more detailed breakdown of
Precision BioSciences's finances. If any of them are yellow this
indicates they may be out of proportion and red means they relate to one of the
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
Low level of unsold assets.
Debt is covered by short term assets, assets are 2.6x debt.
Nearly all companies have debt. Debt in itself isn’t
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.
The graphic below shows equity (available funds) and debt, we ideally want to
see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and
whether the level has increased over the past 5 years.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Mr. Matthew R. Kane, also known as Matt, co-founded Precision BioSciences, Inc. and has been its President, Chief Executive Officer and director since inception in 2006. Mr. Kane has a wealth of life science business development and technical experience. He also serves as a Venture Partner at NextGen Venture Partners. Previously, Mr. Kane was an integral part of Suros Surgical Systems, a venture-backed, breast cancer-focused firm. Mr. Kane was named one of the 40 Under 40 by the Triangle Business Journal and has worked with two seed stage venture capital firms. He received his M.S. in Bio Engineering from the Rose-Hulman Institute of Technology and an MBA from Duke University.
Insufficient data for Matt to compare compensation growth.
Insufficient data for Matt to establish whether their remuneration is reasonable compared to companies of similar size in Germany.
Management Team Tenure
Average tenure and age of the
management team in years:
The average tenure for the Precision BioSciences management team is less than 2 years, this suggests a new team.
Co-Founder & CTO
Chief Financial Officer
Director of Human Resources
Chief People Officer
Senior Vice President of Cell Therapy
Chief Development Officer
Chief Medical Officer
Chief Executive Officer of Elo Life Systems
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The average tenure for the Precision BioSciences board of directors is over 10 years, this suggests they are a seasoned and experienced board.
Precision BioSciences, Inc. operates as a genome editing company and develops therapeutic products in the United States. It operates through two segments, Therapeutic and Food. The company offers ARCUS, a genome editing platform to cure cancers and genetic disorders. The Therapeutic segment develops allogeneic CAR T immunotherapy that recognizes and kills cancer cells; and engages in the in vivo gene correction activities. This segment develops PBCAR0191, is an allogeneic CAR T cell therapy targeting the tumor target CD19 for acute lymphoblastic leukemia and non-hodgkin lymphoma; and CD20, BCMA, and CLL-1, CAR T cell therapies targeting the tumor antigens. The Food segment develops food and nutrition products; and pre-breeding materials, a gene edited crop intermediate that could be integrated into breeding program and use in producing new crop varieties. The company has development and commercial license agreement with Shire Plc for research and development of individual T cell modifications; collaboration agreement with Gilead Sciences, Inc. to co-develop a product candidate to cure chronic Hepatitis B infection. Precision BioSciences, Inc. was founded in 2006 and is headquartered in Durham, North Carolina.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.